196 related articles for article (PubMed ID: 34112701)
21. Blocking activator protein 1 activity in donor cells reduces severity of acute graft-versus-host disease through reciprocal regulation of IL-17-producing T cells/regulatory T cells.
Park MJ; Moon SJ; Lee SH; Kim EK; Yang EJ; Min JK; Park SH; Kim HY; Yang CW; Cho ML
Biol Blood Marrow Transplant; 2014 Aug; 20(8):1112-20. PubMed ID: 24813170
[TBL] [Abstract][Full Text] [Related]
22. Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM).
Taylor PA; Panoskaltsis-Mortari A; Freeman GJ; Sharpe AH; Noelle RJ; Rudensky AY; Mak TW; Serody JS; Blazar BR
Blood; 2005 Apr; 105(8):3372-80. PubMed ID: 15618467
[TBL] [Abstract][Full Text] [Related]
23. Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.
Li JM; Giver CR; Lu Y; Hossain MS; Akhtari M; Waller EK
Immunotherapy; 2009 Jul; 1(4):599-621. PubMed ID: 20191089
[TBL] [Abstract][Full Text] [Related]
24. Inhibiting retinoic acid signaling ameliorates graft-versus-host disease by modifying T-cell differentiation and intestinal migration.
Aoyama K; Saha A; Tolar J; Riddle MJ; Veenstra RG; Taylor PA; Blomhoff R; Panoskaltsis-Mortari A; Klebanoff CA; Socié G; Munn DH; Murphy WJ; Serody JS; Fulton LM; Teshima T; Chandraratna RA; Dmitrovsky E; Guo Y; Noelle RJ; Blazar BR
Blood; 2013 Sep; 122(12):2125-34. PubMed ID: 23814022
[TBL] [Abstract][Full Text] [Related]
25. Early myeloid-derived suppressor cells (HLA-DR
Wang K; Lv M; Chang YJ; Zhao XY; Zhao XS; Zhang YY; Sun YQ; Wang ZD; Suo P; Zhou Y; Liu D; Zhai SZ; Hong Y; Wang Y; Zhang XH; Xu LP; Liu KY; Huang XJ
J Hematol Oncol; 2019 Mar; 12(1):31. PubMed ID: 30885244
[TBL] [Abstract][Full Text] [Related]
26. Intestinal helminths regulate lethal acute graft-versus-host disease and preserve the graft-versus-tumor effect in mice.
Li Y; Chen HL; Bannick N; Henry M; Holm AN; Metwali A; Urban JF; Rothman PB; Weiner GJ; Blazar BR; Elliott DE; Ince MN
J Immunol; 2015 Feb; 194(3):1011-20. PubMed ID: 25527786
[TBL] [Abstract][Full Text] [Related]
27. The balance between donor T cell anergy and suppression versus lethal graft-versus-host disease is determined by host conditioning.
Gonzalez M; Quezada SA; Blazar BR; Panoskaltsis-Mortari A; Rudensky AY; Noelle RJ
J Immunol; 2002 Nov; 169(10):5581-9. PubMed ID: 12421935
[TBL] [Abstract][Full Text] [Related]
28. Short Course of Post-Transplantation Cyclophosphamide and Bortezomib for Graft-versus-Host Disease Prevention after Allogeneic Peripheral Blood Stem Cell Transplantation Is Feasible and Yields Favorable Results: A Phase I Study.
Al-Homsi AS; Cole K; Bogema M; Duffner U; Williams S; Mageed A
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1315-20. PubMed ID: 25765556
[TBL] [Abstract][Full Text] [Related]
29. BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT.
Copsel SN; Lightbourn CO; Barreras H; Lohse I; Wolf D; Bader CS; Manov J; Kale BJ; Shah D; Brothers SP; Perez VL; Komanduri KV; Wahlestedt C; Levy RB
Front Immunol; 2018; 9():3104. PubMed ID: 30733722
[TBL] [Abstract][Full Text] [Related]
30. Modulation of allogeneic CD8+ T-cell response by DZNep controls GVHD while preserving hematopoietic chimerism.
Wang J; Li L; Xu M; Rong R; Zhu T
Transplantation; 2013 Nov; 96(9):774-81. PubMed ID: 23900211
[TBL] [Abstract][Full Text] [Related]
31. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma.
Fowler DH; Gress RE
Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730
[TBL] [Abstract][Full Text] [Related]
32. Bone marrow-derived mesenchymal stem cells decrease acute graft-versus-host disease after allogeneic hematopoietic stem cells transplantation.
Tian Y; Deng YB; Huang YJ; Wang Y
Immunol Invest; 2008; 37(1):29-42. PubMed ID: 18214798
[TBL] [Abstract][Full Text] [Related]
33. MEK inhibitors selectively suppress alloreactivity and graft-versus-host disease in a memory stage-dependent manner.
Shindo T; Kim TK; Benjamin CL; Wieder ED; Levy RB; Komanduri KV
Blood; 2013 Jun; 121(23):4617-26. PubMed ID: 23575444
[TBL] [Abstract][Full Text] [Related]
34. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
Edinger M; Hoffmann P; Ermann J; Drago K; Fathman CG; Strober S; Negrin RS
Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844
[TBL] [Abstract][Full Text] [Related]
35. Non-myeloablative hematopoietic stem cell transplantation (NST) in the treatment of human malignancies: from animal models to clinical practice.
Shimoni A; Nagler A
Cancer Treat Res; 2002; 110():113-36. PubMed ID: 11908195
[TBL] [Abstract][Full Text] [Related]
36. Protection from lethal murine graft-versus-host disease without compromise of alloengraftment using transgenic donor T cells expressing a thymidine kinase suicide gene.
Drobyski WR; Morse HC; Burns WH; Casper JT; Sandford G
Blood; 2001 Apr; 97(8):2506-13. PubMed ID: 11290616
[TBL] [Abstract][Full Text] [Related]
37. GSK3 inhibition prevents lethal GVHD in mice.
Klamer G; Shen S; Song E; Rice AM; Knight R; Lindeman R; O'Brien TA; Dolnikov A
Exp Hematol; 2013 Jan; 41(1):39-55.e10. PubMed ID: 22999867
[TBL] [Abstract][Full Text] [Related]
38. Kinase Inhibition as Treatment for Acute and Chronic Graft-
Braun LM; Zeiser R
Front Immunol; 2021; 12():760199. PubMed ID: 34868001
[TBL] [Abstract][Full Text] [Related]
39. Curcumin attenuates acute graft-versus-host disease severity via in vivo regulations on Th1, Th17 and regulatory T cells.
Park MJ; Moon SJ; Lee SH; Yang EJ; Min JK; Cho SG; Yang CW; Park SH; Kim HY; Cho ML
PLoS One; 2013; 8(6):e67171. PubMed ID: 23840617
[TBL] [Abstract][Full Text] [Related]
40. β2-Adrenergic receptor activation on donor cells ameliorates acute GvHD.
Mohammadpour H; Sarow JL; MacDonald CR; Chen GL; Qiu J; Sharma UC; Cao X; Herr MM; Hahn TE; Blazar BR; Repasky EA; McCarthy PL
JCI Insight; 2020 Jun; 5(12):. PubMed ID: 32437333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
